Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00399438 | A Study of BMS-562086 in Patients With Irritable Bowel Syndrome | PHASE2 | COMPLETED | 39 | — | — | Dec 1, 2006 | Jan 1, 2008 | Sep 26, 2008 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | 0 mg |
| 2 | OTHER | 25 mg |
| 3 | OTHER | 100 mg |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Tablets, Oral, once daily, 2 weeks |
| BMS-562086 | DRUG | Tablets, Oral, once daily, 2 weeks |
Inclusion Criteria: * Female subjects with D-IBS symptoms based on Rome II criteria and the subject's responses to the Bowel Disease Questionnaire Exclusion Criteria: * Clinically significant prolonged diarrhea with dehydration requiring IV fluid within 60 days prior to baseline visit
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Ardelyx, Inc. | ARDX | 4 | PHASE3 | Tenapanor |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | — | Undisclosed |
| Johnson & Johnson | JNJ | 1 | — | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | NA | Undisclosed |